Introduction It is currently unclear which cyclin-dependent kinase 4/6 (CDK4/6) inhibitor,
combined with endocrine therapy, is the preferred treatment approach in patients with …

Background The efficiency and safety of sacituzumab govitecan (SG) for the therapy of
hormone receptor-positive (HR+)/human epidermal receptor 2-negative (HER2-) metastatic …

Abstract Background and Objective Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors
improve progression-free survival when combined with endocrine therapies in patients with …

Cancer is the second leading cause of mortality in EU countries, and the needs to tackle
cancer are obvious. New scientific understanding, techniques and methodologies are …

Objective The clinical efficacy and safety profile of trastuzumab deruxtecan (T-DXd) have
been demonstrated in previously treated patients with human epidermal growth factor …

Purpose Trastuzumab deruxtecan has been shown to be effective for advanced breast
cancer with low levels of human epidermal growth factor receptor 2. To optimize the …

Background In patients with advanced non-small cell lung cancer (aNSCLC), cemiplimab
plus chemotherapy prolonged overall survival (OS) and progression-free survival (PFS) …

BACKGROUND: Breast cancer is the most prevalent type of cancer in women in the United
States. Ribociclib plus fulvestrant combination therapy gained US Food and Drug …

Introduction It is currently unclear which cyclindependent kinase 4/6 (CDK4/6) inhibitor,
combined with endocrine therapy, is the preferred treatment approach in patients with …

Background Patients with hormone receptor-positive, HER2-negative breast cancer who
have residual invasive disease after neoadjuvant chemotherapy (NACT) are at a high risk of …